NPM1 and acute myeloid leukemia: Krönke et al. evaluated the prognostic impact of MRD levels in 245 NPM1-mutated AML patients, of whom 45 patients received allogeneic HSCT.13 Again, NPM1 MRD levels were a significant prognostic marker for remission duration and overall survival (OS).